Navigation Links
Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients
Date:11/1/2008

N A (58%). Depression was most common at 29%. Suicidal behavior including ideation, suicidal attempts, and completed suicides occurred in 1% of patients during or shortly after completing treatment with PEGINTRON.

The following serious or clinically significant adverse events have been reported at a frequency less than 1% with PEGINTRON or interferon alpha: Severe decreases in neutrophil or platelet counts, hypothyroidism, hyperglycemia, hypotension, arrhythmia, ulcerative and hemorrhagic colitis, development or exacerbation of autoimmune disorders including thyroiditis, RA, systemic lupus erythematosus, psoriasis, pulmonary disorders (dyspnea, pulmonary infiltrates, pneumonitis and pneumonia, some resulting in patient deaths), urticaria, angioedema, bronchoconstriction, anaphylaxis, retinal hemorrhages, and cotton wool spots.

In the PEGINTRON/REBETOL combination trial, the incidence of serious adverse events was 17% in the PEGINTRON/REBETOL groups compared to 14% in the INTRON A/ REBETOL group. The incidence of severe adverse events in the PEGINTRON/REBETOL combination therapy trial was 23% in the INTRON A/REBETOL group and 31-34% in the PEGINTRON/REBETOL groups. Dose reductions due to adverse reactions occurred in 42% of patients receiving PEGINTRON (1.5 mcg/kg)/REBETOL and in 34% of those receiving INTRON A/REBETOL.

In a study with weight-based ribavirin, there was a higher rate of anemia among patients in the weight-based dosing group (29%) compared to the flat-dosing group (19%). The majority of these cases were mild and responded to dose reductions. Serious adverse events were similar between the two groups (12%), and discontinuations for adverse events (15% in weight-based dosing and 14% in flat dosing) were also similar. Dose modifications due to adverse events occurred more frequently in the weight-based dosing group (29%) compared to the flat-dosing (23%) group.

Additional Safety Information

Relapse of drug addiction/over
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response
2. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
3. Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL
4. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
5. Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
6. Top-Line Results of Boceprevir Phase II Study Showed High Rate of Sustained Response (SVR) in Genotype 1 Treatment-Naive Hepatitis C Patients
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
9. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
10. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... -- June 28 th , 2014 – Oncolab, the ... cancer test, is making its AACC debut (booth #4051) at ... is a serum-based in vitro immunoassay, has been run for ... in the fight against cancer recurrence. Photo - ... million cancer survivors in the US alone, the race is ...
(Date:7/28/2014)... July 28, 2014 Reportlinker.com announces that ... its catalogue: Portugal Pharmaceuticals and ... http://www.reportlinker.com/p0207141/Portugal-Pharmaceuticals-and-Healthcare-Report-Q3-2014.html Includes 3 ... Faster-than-expected economic growth last quarter has led us ... upwards. As forecast previously, BMI expects ...
(Date:7/28/2014)... July 28, 2014  Serco Inc., a provider ... Company has been awarded a re-compete contract to ... and its Deployable Medical Systems.  Serco will provide ... to provide world-class healthcare to meet warfighter and ... the globe. The five year contract has a ...
Breaking Medicine Technology:Oncolab, Inc. Exhibits Pioneering AMAS Cancer Test at AACC 2Portugal Pharmaceuticals and Healthcare Report Q3 2014 2Portugal Pharmaceuticals and Healthcare Report Q3 2014 3Portugal Pharmaceuticals and Healthcare Report Q3 2014 4Serco Awarded $22.7 Million Contract to Support Deployable Medical Systems 2
... Sept. 8 FluoroPharma, Inc. announced today ... Scientific Advisor,will report on two preclinical studies ... (PET) molecular imaging agents for detection,of Alzheimer,s ... World Molecular,Imaging Congress, in Nice, France on ...
... PRINCETON, N.J., Sept. 8 Medarex, Inc.,(Nasdaq: ... milestone payment for an,undisclosed amount from its licensing ... is a result of the submission of an ... clinical development of an antibody,generated by Medarex,s UltiMAb(R) ...
Cached Medicine Technology:FluoroPharma, Inc. to Report Preclinical Data on Alzheimer's Disease and Prostate Cancer PET Imaging Agents 2FluoroPharma, Inc. to Report Preclinical Data on Alzheimer's Disease and Prostate Cancer PET Imaging Agents 3Medarex Receives Milestone Payment from Pfizer for Investigational New Drug Application Filing 2Medarex Receives Milestone Payment from Pfizer for Investigational New Drug Application Filing 3
(Date:7/28/2014)... Philadelphia, PA (PRWEB) July 28, 2014 ... die each year from metastatic breast and prostate cancers ... when the cancer has spread to other parts of ... brain. Now researchers at Drexel University College of ... target they identified that inhibits metastatic progression by blocking ...
(Date:7/28/2014)... Randy Dotinga HealthDay Reporter ... it takes humans just milliseconds to look at someone,s face ... new study finds that certain facial features seem to trigger ... shape and size of the mouth, for example, appear directly ... keys to attractiveness. The study findings suggest that ...
(Date:7/28/2014)... of a surgical procedure to treat severe chronic migraine ... percent of the time in patients treated at Massachusetts ... of Plastic and Reconstructive Surgery report that more than ... all of whom had headaches associated with compression ... year later. The team,s paper has received advance ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 Thousands of ... on behalf of individuals who were allegedly injured by ... continue to move forward in U.S. District Court, Northern ... an Order issued on July 18, 2014, U.S. District ... filed by the Plaintiffs’ Steering Committee that sought the ...
(Date:7/28/2014)... 2014 Glutamine is the most abundant ... to be conditionally essential during times when the body ... recovery & Immune System Support. , Having a heavy ... produces, supplementing with additional glutamine may be advantageous. Glutamine ... the body, digestion and immune system function. Stress on ...
Breaking Medicine News(10 mins):Health News:Drexel Scientists Develop Compound to Stop Spread of Metastatic Cancer Cells 2Health News:Drexel Scientists Develop Compound to Stop Spread of Metastatic Cancer Cells 3Health News:Facial Dimensions May Be Key to First Impressions 2Health News:Facial Dimensions May Be Key to First Impressions 3Health News:Non-endoscopic migraine surgery provides significant symptom relief 2Health News:DePuy Pinnacle Lawsuit News: New Order Issued in Federal Pinnacle Hip Implant Litigation, Bernstein Liebhard LLP Reports 2Health News:DePuy Pinnacle Lawsuit News: New Order Issued in Federal Pinnacle Hip Implant Litigation, Bernstein Liebhard LLP Reports 3Health News:DePuy Pinnacle Lawsuit News: New Order Issued in Federal Pinnacle Hip Implant Litigation, Bernstein Liebhard LLP Reports 4Health News:Betancourt Nutrition Introduces Glutamine Plus with Sustamine® L-Alanyl-L-Glutamine 2Health News:Betancourt Nutrition Introduces Glutamine Plus with Sustamine® L-Alanyl-L-Glutamine 3
... SAN DIEGO, Sept. 14 Amylin Pharmaceuticals,Inc. (Nasdaq: ... at,an investor reception during the 43rd Annual Meeting of ... Wednesday, September 19,2007 at 4:30 a.m. PT / 1:30 ... live presentation will be webcast, and recordings will be ...
... BIRMINGHAM, Ala., Sept. 14 /PRNewswire-USNewswire/,-- ProAssurance Group ... a specialized,professional liability program designed for Michigan,s ... through Physicians Insurance Company,of Wisconsin, Inc. (PIC ... pleased to have the opportunity to serve ...
... product dissolves naturally , THURSDAY, Sept. 13 (HealthDay News) -- ... someone else,s used-up chewing gum. , But relief may be ... non -stick, easy-to-remove version of chewing gum at the BA ... be easily removed from shoes, clothes, hair and sidewalks, and ...
... Sept. 14 Michael Bond has,been named the ... following nearly 30 years in various roles for ... Blade Process,Engineering. Bond has a wealth of experience ... leading edge technologies for,IncisionTech and Specialty Blades. ...
... Stryker,Corporation (NYSE: SYK ) announced today that ... 25, 2007 - 4:30 p.m. Eastern Time UBS ... A simultaneous webcast of the Company,s presentation will ... the For Investors page. The,presentation for the UBS conference ...
... Most people looking for tax advice,usually go to an ... Here,s more on a new report that shows a ... actually not seeing the pros,trained in their field. ... Registered journalists can access video, audio, text, graphics ...
Cached Medicine News:Health News:ProAssurance Group Offers Coverage for Community Based Hospitals in Michigan 2Health News:Specialty Blades, Inc. Expands Management Team With New VP Engineering 2Health News:Stryker to Present at Investor Conference 2
Stryker Instruments, the leader in surgical helmets, offers its 4th generation of personal protection systems for todays surgical environment the Sterishield T4 System....
... The PROVISION Surgical Helmet System from ... and protection. This system helps meet OSHA ... body fluids, while creating a new standard ... addition to the PROVISION Helmet System from ...
...
... ground has a large surface ... For use with minicrocodile clip ... (1.75 in) long, 3.1 cm ... package contains 50 individually sealed ...
Medicine Products: